GAMMA Investing LLC Has $39,000 Stock Holdings in Fulgent Genetics, Inc. (NASDAQ:FLGT)

GAMMA Investing LLC increased its stake in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) by 45.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 2,133 shares of the company’s stock after buying an additional 667 shares during the period. GAMMA Investing LLC’s holdings in Fulgent Genetics were worth $39,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in the company. Millennium Management LLC lifted its holdings in shares of Fulgent Genetics by 34.3% during the 2nd quarter. Millennium Management LLC now owns 958,852 shares of the company’s stock worth $18,813,000 after acquiring an additional 244,981 shares during the period. State Street Corp increased its stake in shares of Fulgent Genetics by 1.4% in the third quarter. State Street Corp now owns 793,545 shares of the company’s stock valued at $17,244,000 after buying an additional 10,868 shares during the period. Divisadero Street Capital Management LP lifted its position in shares of Fulgent Genetics by 46.4% in the 2nd quarter. Divisadero Street Capital Management LP now owns 505,212 shares of the company’s stock worth $9,912,000 after purchasing an additional 160,212 shares during the period. Geode Capital Management LLC boosted its position in shares of Fulgent Genetics by 2.7% during the 3rd quarter. Geode Capital Management LLC now owns 502,869 shares of the company’s stock valued at $10,930,000 after purchasing an additional 13,320 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of Fulgent Genetics by 113.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 338,044 shares of the company’s stock valued at $7,346,000 after acquiring an additional 179,477 shares during the period. 48.06% of the stock is owned by institutional investors and hedge funds.

Fulgent Genetics Stock Down 4.5 %

Fulgent Genetics stock opened at $17.13 on Wednesday. Fulgent Genetics, Inc. has a twelve month low of $16.56 and a twelve month high of $27.56. The firm has a 50 day moving average price of $18.85 and a 200-day moving average price of $20.73. The company has a market capitalization of $523.96 million, a P/E ratio of -3.10 and a beta of 1.40.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Piper Sandler cut their price objective on shares of Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating on the stock in a research report on Monday, November 11th. StockNews.com downgraded Fulgent Genetics from a “hold” rating to a “sell” rating in a report on Wednesday, November 27th.

Insider Activity

In other news, CEO Ming Hsieh sold 2,227 shares of the stock in a transaction on Monday, November 25th. The shares were sold at an average price of $18.26, for a total value of $40,665.02. Following the transaction, the chief executive officer now owns 703,711 shares of the company’s stock, valued at $12,849,762.86. This represents a 0.32 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders sold 3,413 shares of company stock worth $62,321. 31.76% of the stock is owned by corporate insiders.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.